Recombinant Sendai virus vectors for activated T lymphocytes

S. Okano, Y. Yonemitsu, S. Nagata, S. Sata, M. Onimaru, K. Nakagawa, Y. Tomita, K. Kishihara, S. Hashimoto, Y. Nakashima, K. Sugimachi, M. Hasegawa, K. Sueishi

研究成果: Contribution to journalArticle

20 引用 (Scopus)


T-lymphocyte-directed gene therapy has potential as a treatment of subjects with immunological disorders. One current limitation of this therapeutic strategy is low gene transfer efficiency, even when complex procedures are used. We report herein that a recombinant Sendai virus vector (SeV) was able to overcome this issue. Using jellyfish enhanced green fluorescent protein gene (EGFP), we found that SeV was able to transduce and express a foreign gene specifically and efficiently in activated murine and human T cells, but not in naive T cells, without centrifugation or reagents including polybrene and protamine sulfate; the present findings were in clear contrast to those demonstrated with the use of retroviruses. The transduction was selective in antigen-activated T cells, while antigen-irrelevant T cells were not transduced, even under bystander activation from specific T-cell responses by antigens ex vivo. Receptor saturation studies suggested a possible mechanism of activated T-cell-specific gene transfer, ie, SeV might attach to naive T cells but might be unable to enter their cytoplasm. We therefore propose that the SeV vector system may prove to be a potentially important alternative in the area of T-cell-directed gene therapy used in the clinical setting.

ジャーナルGene Therapy
出版物ステータス出版済み - 8 2003

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

フィンガープリント Recombinant Sendai virus vectors for activated T lymphocytes' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Okano, S., Yonemitsu, Y., Nagata, S., Sata, S., Onimaru, M., Nakagawa, K., Tomita, Y., Kishihara, K., Hashimoto, S., Nakashima, Y., Sugimachi, K., Hasegawa, M., & Sueishi, K. (2003). Recombinant Sendai virus vectors for activated T lymphocytes. Gene Therapy, 10(16), 1381-1391.